Ad
related to: Novartis AG- Contact Us
Contact a PYLARIFY sales
representative to stay updated.
- PYLARIFY Imaging Sites
Find or register a PYLARIFY
imaging site.
- PYLARIFY Case Studies
Review actual case study
findings for PYLARIFY.
- Resources for PYLARIFY
Discover downloadable guides for
health care professionals.
- Contact Us
Search results
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Zacks via Yahoo Finance· 2 hours agoNovartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2024 results on Apr 23....
Wealth Alliance Sells 177 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 10 hours agoWealth Alliance lessened its position in shares of Novartis AG (NYSE:NVS – Free Report) by 4.9% in the fourth quarter, according to the company in its most ...
Tyche Wealth Partners LLC Acquires Shares of 2,137 Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 7 hours agoTyche Wealth Partners LLC acquired a new stake in Novartis AG (NYSE:NVS – Free Report) during the fourth quarter, according to its most recent filing with ...
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Benzinga via Yahoo Finance· 1 hour agoFollowing an investigation announced in November last year, the FDA said on Thursday that it would...
Valeo Financial Advisors LLC Has $674,000 Stock Holdings in Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 5 days agoValeo Financial Advisors LLC decreased its stake in Novartis AG (NYSE:NVS – Free Report) by 2.4% during the 4th quarter, according to the company in its ...
US FDA mandates label updates on CAR-T cancer therapies
Reuters via Yahoo News· 18 hours agoThe health regulor has required related updates to other sections of the label such as warnings and...
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Zacks via Yahoo Finance· 3 days agoNovartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for...
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years - Novartis...
Benzinga· 2 days agoNovartis AG NVS released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta (ofatumumab) treatment ...
9 Best Biotech ETFs for 2024
GoBankingRates via AOL· 2 hours agoBiotechnology uses living organisms to develop new medicines and technologies that benefit both environmental and social stratospheres. If you're...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant...
Fort Wayne Journal Gazette· 4 days agoAPPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by...
